STING1 and hepatocellular carcinoma: Clarifying the molecular mechanisms of STING agonists against HCC or liver metastases, searching for and screening out predictive markers that are suitable for STING agonist treatment, and selecting appropriate therapeutic doses to improve the effect of STING agonists on tumors and reduce their adverse effects are crucial for the clinical development of STING agonists.